NIH VideoCast - Rapid COVID-19 Vaccine Development: An Example of the Prototype Pathogen Approach for Pandemic Preparedness

Skip Navigation

Rapid COVID-19 Vaccine Development: An Example of the Prototype Pathogen Approach for Pandemic Preparedness

0 seconds of 0 secondsVolume 90%

00:25

00:00

00:00

5,560 Views

Air date:	Wednesday, April 22, 2020, 3:00:00 PM Time displayed is Eastern Time, Washington DC Local
Views:	Total views: 5,560 (2,778 Live, 2,782 On-demand)
Category:	COVID-19
Runtime:	00:56:56
Closed captioning:	Check box to display CC outside of the video Note: You can drag the captioning window around and resize it
Description:	NIH COVID-19 SIG Lecture Series The prototype pathogen approach for pandemic preparedness has been applied to the Middle East respiratory syndrome coronavirus (MERS CoV) over the last seven years. It was informed by structure-based immunogen-design concepts established for respiratory syncytial virus fusion (RSV F) subunit vaccines, and focused on solving coronavirus spike structures, defining mechanisms of CoV neutralization, and evaluating MERS CoV vaccine candidates in collaboration with a commercial mRNA manufacturer. Prior spike protein engineering experience resulted in rapid sequence selection and using the mRNA manufacturing platform provided rapid Good Manufacturing Practice (GMP) production a COVID-19 mRNA vaccine in record time. This candidate was tested in mice in approximately 25 days and humans in approximately 65 days from the time the sequence was released. Clinical and nonclinical evaluation are now proceeding in parallel with hopes to begin efficacy testing before next winter. The proactive preparation not only facilitated vaccine development but provided a stabilized spike protein reagent that is supporting the development of serological assays.

Author:	Barney S. Graham, M.D., Ph.D., Deputy Director, Vaccine Research Center, NIAID, NIH

CIT Live ID:	36377
Permanent link:	https://videocast.nih.gov/watch=36377

Related Videos...